Abstract. Supra-clavicular lymph node metastasis from ovarian cancer is rare. The present study reports the unique case of a 43-years-old patient who initially presented with left supra-clavicular lymph node metastasis, and was nulliparous. According to fine-needle aspiration cytology of the metastatic left supra-clavicular lymph nodes and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) scan, the patient was diagnosed with poorly differentiated serous carcinoma of ovarian cancer, stage IV. Following two cycles of platinum-based chemotherapy, PET/CT showed that the patient had achieved a complete response. Next, cytoreductive surgery was performed and the postoperative histological findings showed that the patient had achieved a complete pathological response. According to NCCN Clinical Practice Guidelines in Oncology, the patient was stage IV and four cycles of chemotherapy were provided, with no recurrence observed during 3 years of follow-up. This case indicates that patients who initially present with distant metastatic lymph nodes and are nulliparous might have a better prognosis and avoid overtreatment.
Introduction
Approximately 75% of patients with ovarian cancer are diagnosed with advanced disease, namely, International Federation of Gynecology and Obstetrics (FIGO) stage III-IV disease (1) . Ovarian cancer metastasizes mainly through direct extension and abdominal implantation, followed by use of lymphatic channels, particularly the intra-peritoneal route, so that most advanced ovarian cancer is confined in the abdominal and pelvic cavity (2, 3) . Distant metastasis occurs in patients with stage IV disease, mainly through the lymphatic channels and via hematogenous dissemination, and these metastatic sites can be the lungs, liver, brain and distant lymph node. Distant metastatic lymph nodes are rare in the primary presence of ovarian cancer (4) . Only a few cases of supra-clavicular, axillary, mediastinal and inguinal lymph node metastasis have been reported (5) (6) (7) (8) .
The standard treatment for ovarian cancer is surgical staging and maximal cytoreduction, with adjuvant platinum and taxane combination chemotherapy. For patients with stage III to IV disease whose tumor is too large to be treated surgically, neoadjuvant chemotherapy (NACT) may be considered as the primary treatment. No more than four cycles of NACT and interval debulking surgery can be a good option for these patients. A new radiological study should be performed following every two cycles of NACT. A complete pathological response (pCR) is uncommon in patients who have received chemotherapy, so is uncommon in ovarian cancer. Only a small percentage of patients (6.5%) achieve a pathologic complete response (pCR) following NACT (9,10). Furthermore, pCR in patients with advanced ovarian cancer receiving NACT is associated with longer progression-free survival and overall survival times compared with those in women with no pCR (10) .
The present study reports the case of a patient who initially presented with metastatic left supra-clavicular lymph nodes from ovarian cancer and achieved a pCR following two cycles of NACT.
Case report
A 43-year-old woman was admitted to the Department of Radiotherapy and Chemotherapy (Gynecological Oncology) in Zhongnan Hospital of Wuhan University (Wuhan, China) in January 2014, with complaints of several enlarged left supra-clavicular lymph nodes that had been apparent for 1 week. A number of the enlarged lymph nodes were tender. Chest computed tomography (CT) showed no abnormality in the bilateral lungs, but a magnetic resonance imaging scan of the pelvis showed gross masses. In addition, although the patient had undergone in-vitro fertilization twice, no success had been obtained, and the patient's menstrual cycle was 28/3 days, which means the first day of the period follows the first day of the preceding period by 28 days, and the duration of flow is 3 days. The patient was stage IV by FIGO staging system (1) and a complete resection was difficult, so NACT was planned as the primary treatment followed by interval debulking surgery. The NACT regimen was a platinum and taxane combination (260 mg paclitaxel and 850 mg carboplatin, every 3 weeks). The CA125 level following the first cycle was 41.0 and the second cycle was 14.6 U/ml. The CA125 level decreased to normal following the second cycle of NACT. PET/CT was used for follow-up imaging subsequent to two cycles of NACT, and it showed no markedly increased FDG uptake in the areas that were abnormal on the first PET/CT scan (Figs. 4 and 5) . The patient achieved a complete response (CR) following two cycles of NACT. Next, the patient was managed with surgery plus hyperthermic intraoperative interperitoneal chemotherapy (HIPEC). The surgical therapy included a total laparoscopic hysterectomy, a bilateral salpingo-oophorectomy, an abdominal wall lesionectomy, an omentectomy, and a pelvic and para-aortic lymphadenectomy. Intraoperative views concluded that the uterus and bilateral adnexa were normal, that a small amount of ascites was present in the pelvic cavity, that there was no evident abnormality in the bowel, the large omentum, on the surface of the liver and spleen, and that only four small lesions were in the right lower abdominal wall. All specimens were sent for histopathological examination. Intraoperative rapid frozen section (frozen at -20˚C, thickness was 5 µm; observed under a phase-contrast positive microscope at room temperature) indicated a lack of malignant cells. Next, lobaplatin (50 mg) was administered, at a temperature ranging from 42-43˚C, for 60 min. The second HIPEC with same dose and temperature as the first HIPEC was completed 3 days later. Final histological findings detected no malignant cells in the bilateral adnexa or the omentum, and the pelvic and para-aortic lymph nodes were confirmed to exhibit only chronic inflammation (Fig. 6) . pCR was confirmed according to the postoperative histological findings. The patient was administered another four cycles of chemotherapy (270 mg paclitaxel and 120 mg nedaplatin, every 3 weeks). No recurrence was determined during 3 years of follow-up. All the primary antibodies were provided by OriGene Technologies, Inc. (Beijing China), and incubated for 20 min at 3-8˚C. The secondary antibody was a Bond Polymer Refine Detection goat anti-rabbit poly-horseradish peroxidase-conjugated antibody (catalog number: DS9800; Leica Microsystems, Inc., Buffalo Gove, IL, USA), and was incubated for 40 min at room temperature at a ready-to-use dilution.
Discussion
Ovarian cancer is caused by a variety of factors, including genetic, environment and reproductive factors. One of the known risks of ovarian cancer is being childless; women who give birth multiple times have an 8% reduction in risk for each additional pregnancy compared with nulliparous women (11) . The patient in the present study was not able to become pregnant despite undergoing IVF twice. Ovarian cancer is confined to the intraperitoneal route of dissemination by the direct exfoliation of malignant cells. The cancer can also metastasize through the lymphatic channels and the hematogenous route to the retroperitoneal and extra-peritoneal lymph nodes and other distant sites, including the lungs and bones (4, 12) . Distant metastatic lymph nodes can occur at the time of diagnosis of ovarian cancer or during its evolution.
Ovarian cancer with metastatic lymph nodes is stage IV disease and the prognosis of these patients is naturally poor. Data from the literature concerning distant metastases are scarce, and much less is known about the effect of treatment and the prognosis of these patients compared with stage IV patients without distant metastases. A CR has rarely been reported in cases of ovarian cancer with metastatic lymph nodes. A review of the literature on ovarian cancer with distant metastatic lymph nodes, including supra-clavicular (5, 13, 14) , axillary (6, (15) (16) (17) (18) (19) (20) (21) (22) , and inguinal (8,23) lymph node metastasis, is shown in Table II . These reports all emphasized how rare these diseases were, and how to correctly diagnose and provide them with appropriate systemic treatment. The effects of the treatments in these reports were not distinctive from the ordinary measures. Cormio et al (12) analyzed 50 patients with distant disease from 162 patients with epithelial ovarian carcinoma. Only 13 patients presented with distant metastatic disease at the time of diagnosis and not more than 5 patients had metastatic extra-abdominal lymph nodes. The study finally concluded that the duration between the ovarian cancer diagnosis and the documentation of the distant metastasis was the most important prognostic factor associated with survival, and that the survival time was longer when this duration was longer. Cheng et al (7) reported a retrospective study of 20 cases of epithelial ovarian carcinoma with extra-abdominal metastases and 645 cases without extra-abdominal metastases. Only 2 patients presented initially with extra-abdominal metastases at the time of diagnosis, and not more than 3 patients had metastatic extra-abdominal lymph nodes. In conclusion, this study indicated that the Karnofsky performance status (KPS) score, sensitivity of primary chemotherapy, metastatic site and systemic therapy following the diagnosis of extra-abdominal metastases were the factors that were significantly associated with survival. Zang et al (24) reviewed 25 patients with epithelial ovarian cancer who were diagnosed with initial extra-abdominal metastases. The study demonstrated that the prognosis of patients with supraclavicular lymphadenopathy or malignant pleural effusion was improved compared with that for other stage IV patients with epithelial ovarian cancer. The present report may indicate improved treatment effects and a longer survival time compared with other patients with stage IV disease from the aforementioned study (7, 24) , with a KPS score of 1, left supra-clavicular metastatic lymph nodes and active chemotherapy. In fact, subsequent to two cycles of chemotherapy, the patient achieved CR. Intraoperative examination and histopathological examination were negative for disease, as was the histopathological examination following the surgery.
When a patient presents with metastatic lymph nodes, it is crucial to locate the primary tumor and begin active treatment. Due to the use of PET/CT, it is easy to locate the exact origin of metastatic diseases. CR has rarely been achieved following chemotherapy for ovarian cancer, but it is possible. In the present case, the patient presented with distant metastatic lymph nodes and was nulliparous. CR was achieved following two cycles of NACT. Thus, the authors speculate whether patients who initially present with distant metastatic lymph nodes and are nulliparous, as in the present case, experience an improved prognosis and also avoid overtreatment compared with patients presenting differently. Further studies are required to confirm this and to explain the reason why such patients have a better prognosis.
